Mar­tin Shkre­li faces an­oth­er law­suit, this time from in­sur­er, al­leg­ing plans to cre­ate a mo­nop­oly for Dara­prim

The no­to­ri­ous “Phar­ma Bro” Mar­tin Shkre­li prompt­ed na­tion­al out­rage in 2015 when he and then-Tur­ing Phar­ma­ceu­ti­cals raised the price of Dara­prim, the “gold stan­dard” treat­ment of the par­a­sitic in­fec­tion tox­o­plas­mo­sis, from $17.50 to $750 per tablet. De­spite this, he was ul­ti­mate­ly jailed in 2017 for un­re­lat­ed se­cu­ri­ties fraud charges for mis­lead­ing in­vestors in one of his oth­er com­pa­nies, Retrophin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER